Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

  • Technology appraisal guidance
  • TA832
  • Published: 

Register as a stakeholder

Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids [ID3842]

This appeal hearing will hear appeals against the Final Appraisal Document for the above technology by the following organisations:

  • FEmISA

 The appeal panel will convene on Wednesday 7 September 2022 at 10:00am via Zoom to hear oral representations from the appellants.

This page was last updated: